tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks 50 IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

NBIX Stock Latest News

Neurocrine price target raised to $150 from $148 at Morgan Stanley
The FlyNeurocrine price target raised to $150 from $148 at Morgan Stanley
4d ago
NBIX
Neurocrine initiated with a Buy at Truist
PremiumThe Fly
Neurocrine initiated with a Buy at Truist
5d ago
NBIX
Neurocrine Biosciences’ NBI-921352 Study: A Potential Game-Changer for SCN8A-DEE Treatment
PremiumCompany Announcements
Neurocrine Biosciences’ NBI-921352 Study: A Potential Game-Changer for SCN8A-DEE Treatment
9d ago
NBIX
Neurocrine Biosciences’ NBI-921352 Study Update: Implications and Insights
PremiumCompany Announcements
Neurocrine Biosciences’ NBI-921352 Study Update: Implications and Insights
9d ago
NBIX
Neurocrine’s Growth Potential Driven by Ingrezza’s Market Share and Crenessity’s Uptake
PremiumRatings
Neurocrine’s Growth Potential Driven by Ingrezza’s Market Share and Crenessity’s Uptake
11d ago
NBIX
Neurocrine presents one-year data from study of Crenessity
PremiumThe FlyNeurocrine presents one-year data from study of Crenessity
12d ago
NBIX
Neurocrine Biosciences’ Phase 2 Study on NBI-1117568 for Schizophrenia: Key Updates
Premium
Company Announcements
Neurocrine Biosciences’ Phase 2 Study on NBI-1117568 for Schizophrenia: Key Updates
15d ago
NBIX
Strong Sales Growth and Market Dynamics Justify Buy Rating for Neurocrine
Premium
Ratings
Strong Sales Growth and Market Dynamics Justify Buy Rating for Neurocrine
15d ago
NBIX
Neurocrine Biosciences Completes Phase 3 Study on Valbenazine for Schizophrenia
PremiumCompany Announcements
Neurocrine Biosciences Completes Phase 3 Study on Valbenazine for Schizophrenia
16d ago
NBIX
Neurocrine initiated with a Buy at Goldman Sachs
PremiumThe Fly
Neurocrine initiated with a Buy at Goldman Sachs
16d ago
NBIX
Buy Rating for Neurocrine Biosciences Inc. Driven by Crenessity Launch and Discounted Valuation
PremiumRatings
Buy Rating for Neurocrine Biosciences Inc. Driven by Crenessity Launch and Discounted Valuation
16d ago
NBIX
Neurocrine price target raised to $174 from $152 at UBS
PremiumThe Fly
Neurocrine price target raised to $174 from $152 at UBS
17d ago
NBIX
Neurocrine initiates Phase 1 study of NBIP-01435
PremiumThe FlyNeurocrine initiates Phase 1 study of NBIP-01435
26d ago
NBIX
Neurocrine presents new data analyses from KINECT-HD study
Premium
The Fly
Neurocrine presents new data analyses from KINECT-HD study
29d ago
NBIX
Neurocrine presents new data on patient-reported improvements with INGREZZA
Premium
The Fly
Neurocrine presents new data on patient-reported improvements with INGREZZA
1M ago
NBIX
Neurocrine names Lewis Choi as Chief Information Officer
PremiumThe Fly
Neurocrine names Lewis Choi as Chief Information Officer
2M ago
TMO
NBIX
Neurocrine announces new data from Phase 4 KINECT-PRO study
PremiumThe Fly
Neurocrine announces new data from Phase 4 KINECT-PRO study
2M ago
NBIX
Neurocrine Announces Leadership Transition with New CMO
PremiumCompany Announcements
Neurocrine Announces Leadership Transition with New CMO
2M ago
8K
NBIX
Neurocrine’s NBI-568 Clinical Advancements Justify Buy Rating Amid Competitive Efficacy and Strong Safety Profile
PremiumRatings
Neurocrine’s NBI-568 Clinical Advancements Justify Buy Rating Amid Competitive Efficacy and Strong Safety Profile
2M ago
NBIX
Neurocrine’s NBI-1117568 shows new positive Phase 2 results in schizophrenia
PremiumThe FlyNeurocrine’s NBI-1117568 shows new positive Phase 2 results in schizophrenia
2M ago
NBIX
Neurocrine Holds Annual Meeting, Approves Key Matters
Premium
Company Announcements
Neurocrine Holds Annual Meeting, Approves Key Matters
2M ago
8K
NBIX
Neurocrine reports data from Phase 3 CAHtalyst Pediatric study
Premium
The Fly
Neurocrine reports data from Phase 3 CAHtalyst Pediatric study
2M ago
NBIX

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >